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There is no uniform agreement as to which antihypertensive drugs should be given for initial therapy.  All of the antihypertensive 
agents are roughly equally effective, producing a good antihypertensive response in 30 to 50 percent of cases. Thus, in uncom-
plicated cases, the choice of an antihypertensive drug is not generally made on the basis of efficacy. There is, however, wide 
inter-patient variability as many patients will respond well to one drug but not to another. There are also some predictable differ-
ences, such as black patients generally responding better to monotherapy with a thiazide diuretic or calcium channel blockers 
(CCBs), and relatively poorly to ACE (angiotensin-converting enzyme) inhibitors or beta blockers.
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Introduction
The choice of agent(s) is determined by 
the ability to achieve the ultimate goal of 
antihypertensive therapy: to maximally 
reduce cardiovascular risk without com-
promising quality of life.
Although the different drugs have 
relatively unique qualities, no antihyper-
tensive agent is perfect. Nevertheless, 
currently available choices are highly 
effective, and when used properly, can 
protect almost all patients without induc-
ing significant adverse effects. There is 
a potential problem in both the  govern-
ment and private sectors in that there 
are many restrictive formularies that fre-
quently provide only for the least expen-
sive drugs, even if they are not the most 
appropriate for an individual’s needs.
As more patients with mild hyperten-
sion are being treated with drugs, the 
choice of therapy, particularly of the ini-
tial drug, should be made with care. The 
first drug chosen may have to be taken 
for decades. Therefore, adverse effects 
that may not be obvious must be consid-
ered. However, as noted in virtually all 
trials, most patients will need more than 
one drug to control their hypertension.
Initial therapy
The SAHS (South African Hypertension 
Society) and National Department of 
Health Hypertension Guideline1 recom-
mendation for initiating therapy in un-
complicated hypertension is with a low-
dose thiazide diuretic unless there is a 
specific indication for a drug from an-
other class. It is reasonable to conclude 
that thiazide diuretics provide similar 
cardiovascular benefits in this setting.
This recommendation applies to low 
doses of a thiazide diuretic (e.g. 12.5 
to 25 mg of hydrochlorothiazide). This 
regimen is associated with a low rate 
of metabolic complications, such as 
hypokalaemia, glucose intolerance, and 
hyperuricaemia. However, severe hypo-
natraemia has been observed. 
Thiazides have other actions that 
may be desirable in specific patient 
populations. In particular they lower 
urinary calcium excretion, which may be 
beneficial in patients with hypercalciuria 
and recurrent calcium stones, and in 
those with osteoporosis. 
If low-dose thiazide monotherapy 
fails to attain goal blood pressure in 
uncomplicated hypertensives, an ACE 
inhibitor or ARB (angiotensin receptor 
blocker) or calcium channel blocker can 
be added sequentially. 
The suggestion that calcium channel 
blockers may increase the risk of myo-
cardial infarction in hypertensive pa-
tients has not been confirmed in studies 
using long-acting dihydropyridine. The 
appropriate use of these drugs should 
therefore not be curtailed. 
Monotherapy based upon age and 
race 
The likelihood of a good response is in-
creased when two simple clinical char-
acteristics, age and race, are utilised to 
determine drug treatment. The following 
patients respond best to different types 
of antihypertensive agents used as 
monotherapy:
•  Younger white patients to beta block-
ers and ACE inhibitors (and probably 
ARBs) 
•  Older and black patients to diuretics 
and CCBs 
Support for this differential antihyperten-
sive response with age is supported by 
a study of 56 young white hypertensive 
patients that evaluated the efficacy of 
a cross-over rotation among four main 
classes of drugs. Significantly greater 
responses in both systolic and diastolic 
blood pressure levels were noted with 
the ACE inhibitor and beta blocker than 
with the CCB or diuretic.
The greater efficacy of the CCBs and 
diuretics in elderly white and black hy-
pertensives has also been documented. 
The response of these patients to an 
ACE inhibitor or a beta blocker can be 
enhanced by the addition of a diuretic. 
These different responses may be at 
least partially related to the baseline 
plasma renin activity (PRA) level. 
The ASCOT2 study, however, sug-
gests that beta blockers (atenolol) 
should not be used as first line therapy 
for the treatment of hypertension in the 
absence of other indications for their 
use. 
Response rates to single drug thera-
py for hypertension in blacks over the 
age of 60 years. (Figure 1)
The highest response was noted with 
diltiazem and hydrochlorothiazide (HCTZ) 
and the lowest with captopril. A response 
was defined as a diastolic pressure be-
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low 90 mmHg at the end of the titration 
phase and below 95 mmHg at one year. 
The pattern of response was similar but 
the success rate for each drug was re-
duced by five to fifteen percent if goal 
diastolic pressure was less than 90 
mmHg at one year. There were between 
42 and 53 patients in each group.3
Response rates to single drug thera-
py for hypertension in whites under 
the age of 60. (Figure 2)
There were no significant differences 
in response, except that hydrochlorothi-
azide (HCTZ) appeared to be least ef-
fective. A response was defined as a di-
astolic pressure below 90 mmHg at the 
end of the titration phase and below 95 
mmHg at one year. The pattern of re-
sponse was similar but the success rate 
for each drug was reduced by five to fif-
teen percent if goal diastolic pressure 
was less than 90 mmHg at one year. 
There were between 30 and 39 patients 
in each group.3
Refining drug choices
Any drug that lowers blood pressure un-
less absolutely contraindicated will con-
Figure 2:  Single drug in whites
Antihypertensive response to different drugs in whites 
Indications for specific drugs
Table I:  Recommendations on compelling indications for a specific drug class1
Compelling indications Drug class
Angina Beta blocker OR CCB (rate lowering preferred)
Prior myocardial infarct Beta blocker AND ACE-I (ARB if ACE-I intolerant). 
Verapamil if beta blockers contraindicated. If heart 
failure, see below
Heart failure  ACE-I (ARB if ACE-I intolerant) AND certain beta 
blockers AND aldosterone antagonist
For combination ARB and ACE-I *
Loop diuretics for volume overload
Left ventricular hypertrophy 
(confirmed by ECG)
ARB (preferred) OR ACE-I
Stroke: secondary prevention Low-dose thiazide-like diuretic and ACE-I or ARB
Diabetics type 1 or 2 with or without 
evidence of microalbuminuria or 
proteinuria
ACE-I OR ARB – usually in combination with a di-
uretic
Chronic kidney disease ACE-I or ARB – usually in combination with a diuretic
Isolated systolic hypertension Low-dose thiazide or thiazide-like diuretics OR long-
acting CCB
* Young JB, Dunlap ME, Pfeffer MA, et al. Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity 
(CHARM) Investigators and Committees. Mortality and morbidity reduction with Candesartan in patients with chronic heart 
failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 
2004; 110:2618-2626.
Figure 1:  Single drug in blacks 
Antihypertensive response to different drugs in blacks 
fer protection against target-organ dam-
age. However, the following classes of 
drugs have additional protective prop-
erties in the case of the listed associat-
ed clinical conditions/target-organ dam-
age.
These general recommendations for 
initial therapy should be amended in 
certain clinical settings in which specific 
agents might offer particular benefits 
(See Table 1). These indications include 
the demonstration that ACE inhibitors im-
prove outcomes in a number of high risk 
settings and that beta blockers improve 
survival in patients with systolic heart 
failure (third-generation beta blockers) 
and a prior myocardial infarction.
ACE inhibitors
ACE inhibitors are first-line therapy in 
all patients who have heart failure or 
asymptomatic left ventricular dysfunc-
tion, in all patients who have had an S-T 
elevation myocardial infarction (STEMI), 
in patients with a non S-T elevation myo-
cardial infarction (non-STEMI) who have 
had an anterior infarct, diabetes, or 
systolic dysfunction, and in patients with 
proteinuric chronic renal failure. Combi-
nation therapy with an ARB appears to 
be beneficial in patients with heart fail-
ure and proteinuric chronic renal failure. 
It has been suggested that ACE 
inhibitors and ARBs have a cardio-
protective effect independent of blood 
pressure lowering in patients at high risk 
for a cardiovascular event. 
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ARBs 
The indications for, and efficacy of ARBs 
and ACE inhibitors are much the same. 
An ARB is particularly indicated in pa-
tients who do not tolerate ACE inhibitors 
(mostly because of coughing). 
There is at least one setting in which 
ARBs have specific benefits and in 
which similar trials have not been per-
formed with ACE inhibitors: severe hy-
pertension with ECG evidence of left 
ventricular hypertrophy in LIFE.4 An ARB 
can be used instead of an ACE inhibitor 
in such patients, although it is probable 
that an ACE inhibitor would be equally 
effective. 
Beta blockers
A beta blocker without intrinsic sympa-
thomimetic activity should be given af-
ter an acute myocardial infarction and to 
stable patients with heart failure or as-
ymptomatic left ventricular dysfunction 
(beginning with very low doses to min-
imise the risk and degree of initial wors-
ening of myocardial function). The use 
of beta blockers in these settings is in 
addition to the recommendations for 
ACE inhibitors in these disorders.
Beta blockers are also given for rate 
control in patients with atrial fibrillation, 
for control of angina, and for symptom 
control in a number of other disorders. 
Compared to other antihypertensive 
drugs, during the primary treatment of 
hypertension, beta blockers may be as-
sociated with a small absolute increase 
in the stroke rate (particularly among 
smokers) and perhaps, with atenolol, a 
small increase in mortality. Thus, in the 
absence of a specific indication for their 
use, beta blockers should not be used 
as primary therapy for hypertension.
Diuretics 
A thiazide diuretic should be prescribed 
in the absence of an indication for any 
other specific drug(s) or when goal 
blood pressure has not been attained.
Diuretics should also be given for flu-
id control in patients with heart failure 
or nephrotic syndrome; these settings 
usually require loop diuretics. In addi-
tion, an aldosterone antagonist is indi-
cated in patients with advanced heart 
failure who have relatively preserved re-
nal function and, in patients with less se-
vere disease, for the treatment of hypo-
kalaemia. 
Calcium channel blockers
There are no absolute indications for 
calcium channel blockers in hyperten-
sive patients. Like beta blockers, they 
can be given for rate control in patients 
with atrial fibrillation or for control of an-
gina. 
Other specific settings
Beyond these indications, a number 
of specific recommendations can be 
made for drugs with favourable effects 
in various settings. As an example, an 
alpha blocker may be preferred in older 
men with symptoms of prostatism.
Drug dosing and drug frequency 
The steepest part of the dose response 
curve is frequently seen at lower doses: 
Good responders generally respond to 
low doses with few side effects, while 
higher doses produce more side effects 
often with little further reduction in blood 
pressure.
The theoretical therapeutic and toxic 
effect curves of antihypertensive agents 
vary based upon the administered dose. 
The theoretical effects of a single drug 
given at two different doses (10 and 20 
units) are shown in figure 3. At a dose 
of 10 units, the antihypertensive agent 
has a minimal toxic effect (A’) and a 
moderate therapeutic effect (A). Dou-
bling the dose, however, is associated 
with substantial toxic effects (B’) but little 
increase in therapeutic efficacy (B).5
The issue of dose frequency relates 
to the absence of 24 hour efficacy with 
certain “long-acting” drugs such as the 
angiotensin-converting enzyme inhibitor 
enalapril. Once daily dosing gives a 
greater peak response, but the blood 
pressure tends to return toward base-
line in the early morning hours prior to 
Figure 3:  Dose response curves in hypertension
Dose relation between therapeutic effect and toxicity with antihypertensive drugs 
the next dose. This is of concern, since 
a greater daily blood pressure load and 
early morning abrupt elevation in blood 
pressure can increase cardiovascular 
risk. 
Giving half the dose twice a day pro-
duces a lesser peak effect but a more 
sustained response; however, adher-
ence may be reduced. Drugs that are 
longer-acting, either by inherent proper-
ties or special delivery systems, are the 
better choice. It is prudent, however, to 
check the blood pressure in the morning 
prior to the next dose whenever a once 
daily regimen is used.
Combination therapy
Administering two drugs as initial thera-
py should be considered in patients with 
blood pressure that is more than 20/10 
mmHg above goal blood pressure. This 
strategy may increase the likelihood that 
target blood pressure is achieved in a 
reasonable time period, but should be 
used cautiously in patients at increased 
risk for orthostatic hypotension (such as 
diabetics and the elderly).
In patients with mild hypertension, the 
first-line agent will normalise the blood 
pressure in up to 50 percent of patients. 
A second drug should be considered if 
there is a suboptimal response to initial 
therapy. The rationale behind a combi-
nation regimen is that early addition of 
a second drug may be: (1) as or more 
effective, since many responders to a 
given drug do so at relatively low doses; 
and (2) associated with less toxicity.
Most drug combinations, using 
agents that act by different mecha-
nisms, tend to have an additive effect. 
Examples include an ACE inhibitor with 
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a diuretic or calcium channel blocker. A 
low dose of a thiazide diuretic increas-
es the antihypertensive effect of all oth-
er antihypertensive drugs by minimising 
volume expansion.
An ACE inhibitor or ARB also minimises 
diuretic-induced metabolic abnormali-
ties (such as hypokalaemia, hyperuri-
caemia and hyperlipidaemia) and 
prevents the hypovolaemia-induced 
increase in angiotensin II that normally 
limits the response to the diuretic. 
Potentially unfavourable combina-
tions
Some drug combinations may not have 
an additive antihypertensive effect, such 
as the combination of an ACE inhibitor 
and a beta blocker, or a diuretic and a 
calcium channel blocker. The relative 
lack of efficacy may be explained in part 
by similar mechanisms of action which 
could contribute to a lesser additive 
value when used as combinations. 
There are also combinations that 
have deleterious side effects. In par-
ticular, a beta blocker should be used 
with caution in combination with non-
dihydropyridine CCBs. These drugs can 
lead to profound bradycardia or heart 
block. A beta blocker diuretic combi-
nation is diabetogenic and should be 
avoided especially in obese individuals 
and those with a family history of diabe-
tes mellitus.
In general, however, therapy should 
start with a single drug unless the blood 
pressure is more than 20/10 mmHg over 
the goal.  
See CPD Questionnaire, page 42
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